Pharmaceuticals, Biotechnology and Life Sciences
REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management…
ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing…
First r/r ALL patient dosed in Europe with Cellectis’ UCART22 product candidate manufactured in-houseCellectis implements CLLS52 for the first time…
MINNEAPOLIS, May 04, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the…
EMERYVILLE, Calif., May 04, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the…
Completed enrollment for Phase 2 SEQUEL trial in mild-to-moderate Alzheimer’s disease (AD); topline results expected 2Q 2023 SHINE (AD) trial…
Presented initial clinical data for RLY-2608 at American Association for Cancer Research (AACR) Annual Meeting 2023 Initiated clinical trial for…
– Multiple data readouts anticipated in 2023 from ongoing Phase 2 programsin hepatitis B and D, and influenza – –…
Phase 3 PATHFNDR-1 study topline data expected in 3Q 2023Phase 3 PATHFNDR-2 study topline data expected in 1Q 2024 and…
– Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer…